Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Baptiste Delapierre
Observed name:
B. Delapierre
Institution:
Centre Hospitalier Universitaire de Caen Normandie
Observed institutions:
Inserm,
Normandie Université,
Centre Hospitalier Universitaire de Caen Normandie,
Centre François Baclesse,
Université de Caen Normandie
ORCID:
0000-0002-3247-8637
Observed ORCID:
0000-0002-3247-8637
OpenAlex ID:
A5012457124
Bendamustine-EAM versus BEAM regimen in patients with mantle cell lymphoma undergoing autologous stem cell transplantation in the frontline setting: a multicenter retrospective study from Lymphoma Study Association (LYSA) centers
2020
·
Thomas Hueso
, Thomas Gastinne
, et al.
·
Bone Marrow Transplantation
·
24
Salvage therapy with brentuximab-vedotin and bendamustine for patients with R/R PTCL: a retrospective study from the LYSA group
2022
·
Raphaelle Aubrais
, Krimo Bouabdallah
, et al.
·
Blood Advances
·
21
PDF
Low dose Rituximab for pre-emptive treatment of Epstein Barr virus reactivation after allogenic hematopoietic stem cell transplantation
2019
·
B. Delapierre
, O. Reman
, et al.
·
Current Research in Translational Medicine
·
17
PDF
Large B-cell lymphoma: The LYSA pragmatic guidelines
2025
·
Pierre Sesques
, Guillaume Manson
, et al.
·
European Journal of Cancer
·
8
PDF
Clinical benefit of tafasitamab plus lenalidomide in relapsed or refractory diffuse large Bcell lymphoma: real-world data from the EarlyMIND study
2025
·
Gabriel Brisou
, Jérôme Paillassa
, et al.
·
Haematologica
·
6
Is ibrutinib-related atrial fibrillation dose dependent? Insights from an individual case level analysis of the World Health Organization pharmacovigilance database
2024
·
Joachim Alexandre
, Jonaz Font
, et al.
·
Leukemia
·
6
PDF
Safety and efficacy of CD3xCD20 bispecific antibody for the treatment of primary and secondary central nervous system lymphoma patients: A multicentric retrospective study
2025
·
Adrien Gilbert
, Inès Boussen
, et al.
·
Blood
·
5
PDF
Role of Social Status and Social Environment on Net Survival in Patients with Chronic Lymphocytic Leukemia: A High-Resolution Population-Based Study
2022
·
B. Delapierre
, X. Troussard
, et al.
·
Cancer Epidemiology
·
3
PDF
Nivolumab with or without vinblastine for first-line treatment of elderly patients with Hodgkin lymphoma and coexisting medical conditions: the Niviniho phase II Lysa study
2026
·
Julien Lazarovici
, Sandy Amorim
, et al.
·
Haematologica
·
2
PDF
Brentuximab-vedotin and bendamustine for relapsed or refractory Hodgkin lymphoma: the LYSA real-world experience
2026
·
Gaetan Basile
, Arnaud Neuville
, et al.
·
Haematologica
·
2
PDF
Bruton’s tyrosine kinase inhibitors and cardiovascular risk: a meta-analysis
2026
·
Joachim Alexandre
, Jonaz Font
, et al.
·
European Heart Journal
·
1
Association Between the Renin–Angiotensin System and Ibrutinib-Related Cardiovascular Adverse Events: A Translational Cohort Study
2025
·
Jonaz Font
, Amir Hodzic
, et al.
·
Biomedicines
·
1
PDF
Mise en place de consultations pharmaceutiques initiales et de suivi en onco-hématologie : bilan à deux ans et perspectives
2025
·
Philippe Coulibaly
, Baptiste Bazire
, et al.
·
Annales Pharmaceutiques Françaises
·
1
Tislelizumab, an Anti-PD1 Antibody, in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma in Tirhol Bgb-A317-210: A Prospective Multicenter Lysa Phase 2 Study Conducted in Western Countries
2023
·
Herve Ghesquieres
, Krimo Bouabdallah
, et al.
·
Blood
·
1
PDF
Interleukin 10 (IL10) and IL15 Significantly Decreased in Chronic Myeloid Leukemia Patients Presenting with Tyrosine Kinase Inhibitor (TKI) Withdrawal Syndrome (TWS). Results from the Prospective, Explorative and Multicenter « Kiwis » Study Designed for TWS. Clinicaltrial.Gov ID: NCT03996096; Study Number: 18-206
2023
·
Hyacinthe A. Johnson-Ansah
, Anaïs Briant
, et al.
·
Blood
·
1
PDF
Évaluation en vie réelle de la bendamustine seule ou associée au brentuximab védotine dans les lymphomes T cutanés
2025
·
F. Pélouard
, O. Dereure
, et al.
·
Annales de Dermatologie et de Vénéréologie - FMC
Bendamustine alone or in combination with brentuximab vedotin in advanced or refractory cutaneous T-cell lymphomas: a multicenter retrospective study
2025
·
François Pélouard
, Olivier Dereure
, et al.
·
European Journal of Cancer
Outcomes on peritoneal dialysis in patients with primary kidney disease related to multiple myeloma: A cohort study with data from the French Language Peritoneal Dialysis Registry
2025
·
Laura Jolec
, Clémence Bechade
, et al.
·
Peritoneal Dialysis International
130 | Tislelizumab, an Anti‐pd‐1 Antibody, in Patients With Relapsed/refractory Classical Hodgkin Lymphoma: Final Analysis From the Lysa Phase 2 Tirhol Study Bgb‐a317‐210
2025
·
H. Ghesquières
, K. Bouabdallah
, et al.
·
Hematological Oncology
PDF
361 | Real‐world Outcomes of Patient With Relapsed or Refractory Hodgkin Lymphoma Treated With Brentuximab‐vedotin in Association With Bendamustine: the French Lysa Experience
2025
·
G. Basile
, J. Galtier
, et al.
·
Hematological Oncology
PDF
371 | Synthetic Control Arm From Clinical Trial and Real‐world Cohorts From Lysa Group for Untreated Older Classical Hodgkin Lymphoma for Innovative Clinical Trial Designs
2025
·
H. Ghesquieres
, F. Claves
, et al.
·
Hematological Oncology
PDF
Show more works
View as search
Works count:
21
Citation count:
99
H-index:
6
I10-index:
3
Year
Topic
Type